Celebrating Three Years of Allogene

• Post author:andrewkaretas
• Post published:May 10, 2021
• Post category:Perspectives

Continue ReadingCelebrating Three Years of Allogene

@AllogeneTx: This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.

• Post author:andrewkaretas
• Post published:May 10, 2021
• Post category:Twitter

This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.— Allogene Therapeutics (@AllogeneTx)…

Continue Reading@AllogeneTx: This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.

Allogene Therapeutics Reports First Quarter 2021 Financial Results

• Post author:andrewkaretas
• Post published:May 5, 2021
• Post category:Latest News

Allogene Therapeutics Reports First Quarter 2021 Financial Results

Continue ReadingAllogene Therapeutics Reports First Quarter 2021 Financial Results

Revolutionizing Treatment in the Battle Against Blood Cancer

• Post author:andrewkaretas
• Post published:April 28, 2021
• Post category:Perspectives

Continue ReadingRevolutionizing Treatment in the Battle Against Blood Cancer

Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

• Post author:andrewkaretas
• Post published:April 28, 2021
• Post category:Latest News

Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

Continue ReadingAllogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

PD1 TurboCAR™ T Cells: PD1-Resistant CAR T Cells With Programmable Cytokine Signaling Outputs

• Post author:andrewkaretas
• Post published:April 18, 2021
• Post category:PLATFORM/Scientific Publications

Continue ReadingPD1 TurboCAR™ T Cells: PD1-Resistant CAR T Cells With Programmable Cytokine Signaling Outputs

Preclinical Evaluation of ALLO-605, an Allogeneic BCMA TurboCAR T™ Cell Therapy for the Treatment of Multiple Myeloma

• Post author:andrewkaretas
• Post published:December 22, 2020
• Post category:BCMA/Scientific Publications

Continue ReadingPreclinical Evaluation of ALLO-605, an Allogeneic BCMA TurboCAR T™ Cell Therapy for the Treatment of Multiple Myeloma

Investigation of ALLO-316: A Fratricide-Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML

• Post author:andrewkaretas
• Post published:December 18, 2020
• Post category:CD70/Scientific Publications

Continue ReadingInvestigation of ALLO-316: A Fratricide-Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML

First-in-Human Study of the Allogeneic Anti-BCMA ALLO-715 CAR T cell Therapy and the Anti-CD52 Mab ALLO-647 in Relapsed/Refractory Multiple Myeloma (UNIVERSAL Study)

• Post author:andrewkaretas
• Post published:December 9, 2020
• Post category:BCMA/Scientific Publications

Continue ReadingFirst-in-Human Study of the Allogeneic Anti-BCMA ALLO-715 CAR T cell Therapy and the Anti-CD52 Mab ALLO-647 in Relapsed/Refractory Multiple Myeloma (UNIVERSAL Study)

Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery

• Post author:andrewkaretas
• Post published:October 18, 2020
• Post category:FLT3/Scientific Publications

Continue ReadingAllogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery